Skip to main content

Liraglutide (T2DM)


09-20-2017 | Hypoglycemia | EASD 2017 | News

Hypoglycemia: Risk factors and Ramadan

Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.

08-30-2017 | Liraglutide (T2DM) | News

LEADER renal analysis shows protective effect of liraglutide

Analysis of the renal outcomes of patients in the LEADER trial confirms that the glucagon-like peptide-1 analog liraglutide has a renoprotective effect in patients with type 2 diabetes and increased cardiovascular risk.

06-29-2017 | Liraglutide (T2DM) | Updates | News

CHMP recommends update to liraglutide indication

The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending an update to the marketing authorization terms for liraglutide.

Read more

Related topics



Journal articles and book chapters

07-19-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome trial update in diabetes: New evidence, remaining qestions

Seven trials of antihyperglycemic agents from different classes have now been concluded as of May 2017. This review summarizes, compares, and contrasts the key cardiovascular (CV) and non-CV findings from these trials.

Herbst R, Bolton W, Shariff A, Green JB. Curr Diab Rep 2017;17:67. doi:10.1007/s11892-017-0898-8

03-16-2017 | Glycemic control | Review | Article

Metrics for glycemic control: From HbA1c to continuous glucose monitoring

In this review, Kovatchev discusses topics related to the assessment, quantification, and optimal control of glucose fluctuations in diabetes mellitus which are crucial for providing accurate information to the patient and physician.

Nat Rev Endocrinol 2017;13:425–436. doi:10.1038/nrendo.2017.3

Boris P. Kovatchev

11-10-2016 | Type 2 diabetes | Review | Article

Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus

The authors discuss the prevalence of obesity and type 2 diabetes in children and adolescents and summarize published studies on the safety and effectiveness of antihyperglycemic medications in this population.

Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6